Thymic Epithelial Tumors: Treatment

Thymic Epithelial Tumors: overview

This algorithm covers thymic epithelial tumors (thymoma and thymic carcinoma), organized by stage. Resectable stage I to II disease is treated with complete (R0) resection, with adjuvant radiotherapy added for stage II to III disease or a positive margin. Locally advanced stage III to IVA disease is managed with multimodality therapy: neoadjuvant CAP (cisplatin, doxorubicin, cyclophosphamide), then resection, then radiotherapy. Advanced or metastatic stage IVB disease receives first-line cisplatin-based CAP chemotherapy.

For refractory thymic carcinoma, the chart lists lenvatinib as the antiangiogenic option (REMORA), and octreotide or everolimus as non-immunotherapy options that are preferred in thymoma. A key point is that PD-1 inhibitors should be avoided in thymoma because of the high risk of autoimmune toxicity and myocarditis, whereas they remain an option in thymic carcinoma. This is a simplified board-review scaffold that should be verified against current guidelines and primary literature.

Thymic Epithelial Tumors: the algorithm in words

Thymoma and thymic carcinoma by stage; resection, multimodality, and systemic options. Starting point: Thymic epithelial tumor thymoma / carcinoma.

Resectable (stage I-II) (first-line): Surgery: Complete resection (R0) (+ adjuvant RT if stage II-III / margin+).
Locally advanced (III-IVA) (first-line): Multimodal: Neoadjuvant CAP → resection → RT (cisplatin/doxorubicin/cyclophosphamide).
Advanced / metastatic (IVB) (first-line): First-line: CAP chemotherapy (cisplatin-based).
Refractory thymic carcinoma (second-line): Antiangiogenic: Lenvatinib (REMORA); Other: Octreotide / everolimus (thymoma-preferred (non-IO)).

Simplified board-prep scaffold; verify against current guidelines and primary literature. Avoid PD-1 inhibitors in thymoma (high risk of autoimmune toxicity/myocarditis); they are an option in thymic carcinoma.